The lancet oncology
-
The lancet oncology · Jul 2018
Randomized Controlled Trial Multicenter Study Comparative StudyEfficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial.
ABP 980 (Amgen Inc, Thousand Oaks, CA, USA) is a biosimilar of trastuzumab, with analytical, functional, and pharmacokinetic similarities. We compared the clinical safety and efficacy of ABP 980 with that of trastuzumab in women with HER2-positive early breast cancer. ⋯ Amgen.
-
The lancet oncology · Jul 2018
Randomized Controlled Trial Comparative StudyOnce weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
Twice a week carfilzomib at 27 mg/m2 is approved for treatment of relapsed or refractory multiple myeloma. Phase 1/2 CHAMPION-1, the first study exploring once-weekly carfilzomib dosing, established the maximum tolerated dose at 70 mg/m2 in combination with dexamethasone. We aimed to compare progression-free survival in patients with relapsed and refractory multiple myeloma given once weekly carfilzomib or twice weekly carfilzomib. ⋯ Amgen, Inc.
-
The lancet oncology · Jul 2018
Randomized Controlled Trial Multicenter Study Comparative StudyRibociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
In MONALEESA-2, ribociclib plus letrozole showed improved progression-free survival compared with letrozole alone as first-line treatment for postmenopausal patients with hormone receptor (HR)-positive, HER2-negative, advanced breast cancer. MONALEESA-7 aimed to assess the efficacy and safety of ribociclib plus endocrine therapy in premenopausal women with advanced, HR-positive breast cancer. ⋯ Novartis.
-
The lancet oncology · Jul 2018
Randomized Controlled TrialAddition of mitoxantrone and prednisone to ADT.
-
The lancet oncology · Jul 2018
Randomized Controlled TrialConcurrent chemotherapy improves outcomes in HNSCC.